Erlotinib Completed Phase 1 Trials for Unspecified Adult Solid Tumor, Protocol Specific / Malignant Neoplasm of Pancreas Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00033241Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00042809Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00126620Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00276575Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
NCT00320073Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00565487Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
NCT00243854Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
NCT00614653Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
NCT00735306Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
NCT00885066Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
NCT00925769ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer